Inogen Inc - INGN STOCK NEWS

Inogen (Nasdaq: INGN) has announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President of Business Development, effective July 22, 2024. Smith brings nearly 30 years of experience in the medical technology and legal fields, having previously served at Sirtex Medical and Flexion Therapeutics. His extensive background in securities, business development, and intellectual property is expected to strengthen Inogen's legal and business strategy teams. CEO Kevin Smith emphasized the importance of Smith's role in maintaining the company's integrity and compliance.

Inogen, a medical technology company specializing in respiratory products, announced findings from a study published in Pulmonary Therapy. The research, sourced from France's national healthcare database (SNDS), analyzed over 244,000 long-term oxygen therapy patients from 2013-2020. Results demonstrated that portable oxygen concentrators (POCs), alone or combined with other oxygen modalities, improved survival rates and were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen. Additionally, Inogen's higher mobility POC devices, with autonomy over 5 hours, showed better outcomes in survival, healthcare resource use, and related costs than lower mobility devices.

Inogen, Inc. (Nasdaq: INGN) announced their first quarter 2024 financial results, showing an 8.1% increase in total revenue to $78.0 million, accompanied by a total gross margin of 44.1%. The GAAP net loss was $14.6 million, with adjusted net loss at $10.4 million. Adjusted EBITDA was a negative $7.6 million. Inogen expects revenue for the second quarter of 2024 to be in the range of $81 million to $84 million. The company remains focused on revenue growth, profitability, and innovation to enhance their market position.

Inogen, Inc. (INGN) will report its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The call will be accessible via phone and webcast. The company emphasizes transparency by archiving the call and providing a replay option.

Inogen, Inc. (INGN) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Kevin Smith and Michael Bourque to discuss innovative respiratory products. Webcast available for interested parties.

Inogen, Inc. announced the approval of restricted stock units as a material inducement for Michael Bourque, the new Executive Vice President, Chief Financial Officer, and Treasurer. The equity awards consist of 75,000 time-based RSUs and 75,000 performance-based PSUs, potentially reaching a maximum of 150,000 PSUs. The awards are subject to vesting based on Mr. Bourque's continued service and Inogen's performance goals.

Inogen, Inc. (INGN) reported fourth-quarter 2023 revenue of $75.9 million and full-year 2023 revenue of $315.7 million. The company highlighted a focus on revenue growth, profitability, and innovation in 2024. Notable financial results included a decrease in total revenue due to lower business-to-business and direct-to-consumer sales, offset by higher rental revenue. The company reported a GAAP net loss of $26.6 million for Q4 2023 and $102.4 million for full-year 2023. Adjusted net loss was $19.4 million for Q4 2023 and $48.3 million for full-year 2023. Inogen expects first-quarter 2024 revenue of $73 to $74 million, representing 1% to 3% growth compared to Q1 2023.

Inogen, Inc. (INGN) will report Q4 and full year 2023 financial results on February 27, 2024. A conference call and webcast will be hosted the same day. The call will be accessible through dial-in and webcast, with a replay available for three hours after the live webcast ends. Inogen uses its Investor Relations website to disclose material non-public information and comply with disclosure obligations under Regulation FD.

Inogen, Inc. (Nasdaq: INGN) has appointed Michael Bourque as the new Chief Financial Officer, effective March 4, 2024. Bourque brings extensive experience from his roles at Chase Corporation, Keystone Dental, Analogic Corporation, and Axcelis Technologies. Inogen's President and CEO, Kevin Smith, expressed excitement over Bourque's appointment, highlighting his ability to help the company continue delivering superior respiratory solutions. The former Interim CFO, Mike Sergesketter, will remain in an advisory role during the transition. Bourque's appointment marks a pivotal point in Inogen's story, with a focus on delivering value to patients and shareholders.